341
Participants
Start Date
May 2, 2016
Primary Completion Date
December 8, 2017
Study Completion Date
October 17, 2018
Ixekizumab
Administered SC
Placebo
Administered SC
Adalimumab
Administered SC
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Berlin
Klein and Associates MD, PA, Cumberland
Klein and Associates MD, PA, Hagerstown
Shanahan Rheumatology & Immunotherapy, Raleigh
Articularis Healthcare Group, INC dba Columbia Arthritis Ctr, Columbia
Low Country Research Center, North Charleston
Marietta Rheumatology, Marietta
Sarasota Arthritis Center, Sarasota
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taichung
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taichung
Center for Arthritis & Osteoporosis, Elizabethtown
Glacier View Research Institute, Kalispell
Arthritis Consultants, St Louis
Physician Research Collaboration, LLC, Lincoln
Univ of Texas Health Science Center - Houston, Houston
Denver Arthritis Center, Denver
Arthritis Assoc. & Osteoporosis Ctr of Colorado Springs, LLC, Colorado Springs
Arizona Arthritis Research, PLC, Phoenix
Desert Medical Advances, Palm Desert
Care Access Research - Huntington Beach, Huntington Beach
Arthritis Northwest Rheumatology, Spokane
New England Research Associates, Trumbull
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brno
"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician", Hyōgo
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Warszawa
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gwangjin-gu
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul
Eli Lilly and Company
INDUSTRY